Biogen Inc.

Biogen Inc.

BIIBNYSE / NASDAQHealthcareLarge cap

$249.59+$2.46 (+1.0%)

Last close · Data as of Nov 20, 2026

Market cap
$29.0B
P/E
22.4x
EV / EBITDA
12.5x
Revenue
$9.9B
Net margin
13.1%
ROCE
9.5%

+48.4% over the last year

Biogen Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
+2.7%
3M
+16.4%
6M
+32.9%
1Y
+48.4%
5Y
-3.0%

52-week range

Day change +$2.46 (+1.0%) from $247 to $250 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in BIIB, bought on each weekday since 2021.

News & filings

What Biogen filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernReturn on equity of 7.1% against a peer median of 20.5%.

Strengths (1)

  • Operating margin of 25.0% against a peer median of 16.8%.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally.

Read moreShow less

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Sector
Healthcare
Shares outstanding
146.4M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$29.0B
P/E
22.4x
P/B
1.6x
EV / EBITDA
12.5x
EV / Sales
3.3x
P/S
2.9x
52-week high
$254.87
52-week low
$164.42

Profitability

Operating margin
25.0%
Net margin
13.1%
EBITDA margin
26.3%
ROE
7.1%
ROCE
9.5%
ROA
4.4%
Asset turnover
0.34

Growth

Revenue
$9.9B
Revenue growth, 1Y
2.2%
Revenue CAGR, 3Y
-0.9%
Net profit growth, 1Y
-20.8%
Free cash flow
$2.0B

Solvency

Current ratio
2.68
Debt / Equity
0.36
Debt / Assets
0.22
CFO / Net profit
1.71
Cash / Market cap
10.4%

Where the revenue went

Of every $100 of FY2025 revenue, $13 was left as net income.

Biogen Inc. income statement flow, FY2025
Biogen Inc. income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$2.4B
RevenueGross profit$7.5B
Gross profitResearch and development$1.8B
Gross profitSelling, general and administrative$2.4B
Gross profitOther operating expenses$805.2M
Gross profitOperating income$2.5B
Operating incomePretax income$1.6B
Operating incomeInterest and other expense$912.5M
Pretax incomeTax and other$263.6M
Pretax incomeNet income$1.3B

Revenue and net profit

Revenue grew 2.2% in FY2025; net profit is the dashed line.

Biogen Inc. revenue and net profit by fiscal year
Biogen Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$10.2B$3.0B
FY2023$9.8B$1.2B
FY2024$9.7B$1.6B
FY2025$9.9B$1.3B

Cash flows

FY2025: $2.2B from operations, $2.0B free after investment (dashed).

Biogen Inc. operating and free cash flow by fiscal year
Biogen Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$1.4B$1.1B
FY2023$1.5B$1.2B
FY2024$2.9B$2.5B
FY2025$2.2B$2.0B

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$9.9B+2.2%1Y
EBITDA
$2.6B-8.0%1Y
Net profit
$1.3B-20.8%1Y
Cash from operations
$2.2B-23.3%1Y
Free cash flow
$2.0B-21.7%1Y
Revenue CAGR, 3Y
-0.9%
Net profit CAGR, 3Y
-24.9%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$9.9B$2.6B$1.3B$2.0B7.1%+2.2%-20.8%

Monthly returns

Month-by-month returns of BIIB across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$29.4B
Liabilities$11.2B
Equity$18.3B
Paid-in capital$863.1M
Retained earnings$20.6B
Treasury stock$3.0B

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; BIIB highlighted.

P/E against peers

BIIB trades at 22.4x earnings against a peer median of 17.0x (a 32% premium).

Not shown (no positive earnings and no EV / Sales): Centene Corporation, Insmed Incorporated.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Biogen Inc.BIIBthis companyP/E ↑ premium$29.0B22.4x1.6x7.1%12.5x
Zoetis Inc.ZTS$33.3B12.5x10.0x80.2%9.9x
IQVIA Holdings Inc.IQV$31.2B22.9x4.8x20.9%13.0x
Centene CorporationCNC$31.0B-4.6x1.6x-33.4%-6.5x
GE HealthCare Technologies Inc.GEHC$29.0B13.9x2.8x20.1%9.2x
ResMed Inc.RMD$28.2B20.1x4.7x23.5%14.5x
DexCom, Inc.DXCM$28.0B33.5x10.2x30.5%21.0x
Mettler-Toledo International Inc.MTD$23.9B27.4x—-3676.8%20.9x
Insmed IncorporatedINSM$22.7B-17.8x30.8x-172.8%—
Peer median—17.0x4.8x20.5%13.0x

Year-to-date ROI

BIIB since 1 January, against earlier years.

Historical volatility

BIIB's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Biogen Inc. operating margin by fiscal year
Biogen Inc. operating margin by fiscal year
DateOperating margin
FY202228.5%
FY202318.8%
FY202423.6%
FY202525.0%
LineFY2025
Cost of revenueCost Of Revenue$2.4B
Gross profitGross Profit$7.5B
Operating expensesOperating Expense$5.0B
Research and developmentResearch And Development$1.8B
Selling, general and administrativeSelling General And Administration$2.4B
Other operating expensesOther Operating Expenses$290.2M
Depreciation and amortisationDepreciation And Amortization In Income Statement$515.0M
Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement$515.0M
Amortization$515.0M
Amortisation of intangiblesAmortization Of Intangibles Income Statement$515.0M
Total expensesTotal Expenses$7.4B
Pretax incomePretax Income$1.6B

Learn while you research

Academy chapters picked for Biogen Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  3. 03 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  4. 04 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →